Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 61, Issue 2, Pages 543-575Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b00168
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science (KAKENHI) [26860050, 26860049, 16H05090, 16K15121]
- Project for Cancer Research And Therapeutic Evolution (P-CREATE) [16cm0106124j0001]
- Japan Agency for Medical Research and Development (AMED) [15ak0101029h1402, 16ak0101029j1403]
- Ministry of Health and Labor Welfare, Japan
- Takeda Science Foundation
- Takeda Pharmaceutical Co. Ltd.
Ask authors/readers for more resources
Targeted protein degradation using small molecules is a novel strategy for drug development. We have developed hybrid molecules named specific and nongenetic inhibitor of apoptosis protein [IAP]-dependent protein erasers (SNIPERs) that recruit IAP ubiquitin ligases to degrade target proteins. Here, we show novel SNIPERs capable of inducing proteasomal degradation of the androgen receptor (AR). Through derivatization of the SNIPER(AR) molecule at the AR ligand and IAP ligand and linker, we developed 42a (SNIPER(AR)-51), which shows effective protein knockdown activity against AR. Consistent with the degradation of the AR protein, 42a inhibits AR-mediated gene expression and proliferation of androgen-dependent prostate cancer cells. In addition, 42a efficiently induces caspase activation and apoptosis in prostate cancer cells, which was not observed in the cells treated with AR antagonists. These results suggest that SNIPER(AR)s could be leads for an anticancer drug against prostate cancers that exhibit AR-dependent proliferation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available